Ra Pharmaceuticals Inc. (Nasdaq: RARX) reported positive interim results from an ongoing Phase 2 clinical program evaluating RA101495 SC to treat paroxysmal nocturnal hemoglobinuria but the stock price plunged $5.31 to close at $8.92.
Positive interim results for Ra Pharmaceuticals
December 04, 2017 at 16:43 PM EST
